Synta Pharmaceuticals Corp. (NASDAQ:SNTA)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs that address severe medical conditions with potential markets, including cancer and chronic inflammatory diseases.

Recs

0
Player Avatar Dtrifan (53.56) Submitted: 11/13/2007 9:49:01 PM : Outperform Start Price: $8.37 SNTA Score: -42.09

Cancer drug market at a low price

Featured Broker Partners


Advertisement